By Andrew Karpan (May 20, 2022, 7:48 PM EDT) -- Gilead lost its bid to shield its Lexiscan brand of cardiac stress agent from generic competition by Pfizer when the top federal judge in Delaware ruled the new drug wouldn't actually infringe any of Gilead's patents.
Chief District Judge Colm Connolly rendered his 80-page decision Thursday nearly four months after a bench trial in January.
The case was initially brought in 2018, when Gilead Sciences sued numerous generic-drug makers that had applied for approval from the U.S. Food and Drug Administration to market drugs that would compete with Lexiscan, which is used in tests for heart disease and claims to be "the most...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!